Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia

Biological Chemistry

Volumn 389, Issue 6, 2008, Pages 725-730

  Smith Jr , Robert S ^a   Gao, Lin ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Angiogenesis; Blood flow; Bradykinin; Ischemia; Limb; Tissue kallikrein

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BRADYKININ; BRADYKININ B1 RECEPTOR AGONIST; CD31 ANTIGEN; HEMOGLOBIN; KININ; MATRIGEL; MICROSPHERE; TISSUE KALLIKREIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; BLOOD FLOW; BLOOD PRESSURE; CAPILLARY DENSITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMORAL ARTERY; IMMUNOHISTOCHEMISTRY; LASER DOPPLER FLOWMETRY; LIMB ISCHEMIA; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT;

ANIMALS; ARTERIOLES; CAPILLARIES; COLLAGEN; DRUG COMBINATIONS; HEMOGLOBINS; HINDLIMB; INJECTIONS; ISCHEMIA; KININS; LAMININ; LASERS; MALE; MICROSPHERES; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PERFUSION; PROTEOGLYCANS; RATS; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; TISSUE KALLIKREINS;

ADENOVIRIDAE; MUS; RATTUS;

EID: 47549118846     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.084     Document Type: Conference Paper

References (14)

1. Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80.
2. Cao, Y., Hong, A., Schulten, H., and Post, M.J. (2005). Update on therapeutic neovascularization. Cardiovasc. Res. 65, 639-648.
3. Chao, J. and Margolius, H.S. (1979). Isozymes of rat urinary kallikrein. Biochem. Pharmacol. 28, 2071-2079.
4. Chao, J., Li, H.J., Yao, Y.Y., Shen, B., Gao, L., Bledsoe, G., and Chao, L. (2007). Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension 49, 490-497.
5. Emanueli, C. and Madeddu, P. (2001). Targeting kinin receptors for the treatment of tissue ischaemia. Trends. Pharmacol. Sci. 22, 478-484.
6. Emanueli, C., Minasi, A., Zacheo, A., Chao, J., Chao, L., Salis, M.B., Straino, S., Tozzi, M.G., Smith, R., Gaspa, L., et al. (2001a). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125-132.
7. Emanueli, C., Salis, M.B., Stacca, T., Gaspa, L., Chao, J., Chao, L., Piana, A., and Madeddu, P. (2001b). Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 38, 136-141.
8. Emanueli, C., Salis, M.B., Stacca, T., Pintus, G., Kirchmair, R., Isner, J.M., Pinna, A., Gaspa, L., Regoli, D., Cayla, C., et al. (2002). Targeting kinin B1 receptor for therapeutic neovascularization. Circulation 105, 360-366.
9. McLean, P.G., Perretti, M., and Ahluwalia, A. (2000). Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc. Res. 48, 194-210.
10. Mikroulis, D., Papanas, N., Maltezos, E., and Bougioukas, G. (2007). Angiogenic growth factors in the treatment of peripheral arterial disease. Curr. Vasc. Pharmacol. 5, 195-209.
11. Passaniti, A., Taylor, R.M., Pili, R., Guo, Y., Long, P.V., Haney, J.A., Pauly, R.R., Grant, D.S., and Martin, G.R. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67, 519-528.
12. Regoli, D., Rhaleb, N.E., Drapeau, G., and Dion, S. (1990). Kinin receptor subtypes. J. Cardiovasc. Pharmacol. 15 (Suppl. 6), S30-38.
13. Smith, R.S. Jr, Lin, K.F., Agata, J., Chao, L., and Chao, J. (2002). Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler. Thromb. Vasc. Biol. 22, 1279-1285.
14. Xia, C.F., Yin, H., Yao, Y.Y., Borlongan, C.V., Chao, L., and Chao, J. (2006). Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene Ther. 17, 206-219.